title: One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer.
abstract: OBJECTIVE
  To assess the efficacy and safety of ranitidine bismuth citrate plus clarithromycin given for 1 wk in Brazilian patients with peptic ulcer.
  
  
  METHODS
  One hundred and twenty patients with peptic ulcer were randomized in two treatment groups: (1) 1-wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d. or (2) 2-wk regimen of the same treatment. Eradication of the infection was considered when both the histologic examination and the urease test were negative for the infection 3 mo after treatment.
  
  
  RESULTS
  By intention to treat analysis, Helicobacter pylori (H pylori) was eradicated in 73% and 76% of patients, respectively treated for 1 or 2 wk (P>0.05). By per protocol analysis, the eradication rates were 80% and 83%, respectively, in patients treated for 1 or 2 wk (P>0.05). Nine patients (8.2%) reported minor side effects.
  
  
  CONCLUSIONS
  One-week therapy with ranitidine bismuth citrate and clarithromycin is safe, well tolerated and effective for treatment of H pylori infection, and appears to be comparable to the 2-wk regimen in terms of efficacy.
authors.affiliation: Disciplina de Gastroenterologia, Departamento de Clínica Médica, FCM, Universidade Estadual de Campinas, CP 6111, 13081-970, Campinas, São Paulo, Brazil. mesquita@fcm.unicamp.br
authors.forename: Maria Aparecida
authors.initials: MA
authors.lastname: Mesquita
authors.forename: Sonia Letícia Silva
authors.initials: SL
authors.lastname: Lorena
authors.forename: Jazon Romilson Souza
authors.initials: JR
authors.lastname: Almeida
authors.forename: Ciro Garcia
authors.initials: CG
authors.lastname: Montes
authors.forename: Fábio
authors.initials: F
authors.lastname: Guerrazzi
authors.forename: Luciana T
authors.initials: LT
authors.lastname: Campos
authors.forename: José Murilo Rubiota
authors.initials: JM
authors.lastname: Zeitune
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D001938:Brazil; D017291:Clarithromycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D011899:Ranitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; C073340:ranitidine bismuth citrate; D011899:Ranitidine; D017291:Clarithromycin; D001729:Bismuth